UT Health San Antonio-UTSA team studies compounds aimed at brain cancer

January 24, 2023

Basic science generates new drug for treating glioblastoma, the deadliest cancer Glioblastoma multiforme (GBM) is an aggressive brain cancer associated with the worst overall survival rates among all human cancers. Only 65% of GBM patients live one year past diagnosis and only 12% live five years. The late senators Ted Kennedy and John McCain both […]

UT Health San Antonio School of Dentistry awarded $9.8 million NIH grant that could help curb opioid use

January 23, 2023

Study of jaw-joint sensory neurons aimed at creating safer pain treatment The UT Health San Antonio School of Dentistry has received a major five-year, $9.8 million grant from the National Institutes of Health to discover how sensory neurons in the jaw joint and mastication muscles influence and create pain, which could lead to safer drug […]

Increasing brain protein could be a treatment for obesity

January 20, 2023

Drug target that revs up energy expenditure, reduces appetite identified A drug that promotes energy expenditure in the body while suppressing appetite could be a powerful weight loss therapy. Researchers at The University of Texas Health Science Center at San Antonio, the Second Xiangya Hospital of Central South University-China and Baylor College of Medicine reported […]

UT School of Public Health San Antonio inaugural dean receives $1.6 million UT System Faculty STARs award

January 20, 2023

Vasan S. Ramachandran, MD, founding dean of The University of Texas School of Public Health San Antonio, a strategic collaboration between UT Health San Antonio and The University of Texas at San Antonio (UTSA), has received a UT System Faculty Science and Technology Acquisition and Retention (STARs) award for more than $1.6 million to fund […]

A new era in Alzheimer’s treatment

January 11, 2023

Statement from the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio about a timely topic in the news: The U.S. Food and Drug Administration on Friday, Jan. 6, 2023, approved lecanemab, a drug that targets the basic pathophysiology of Alzheimer’s disease. The FDA action is an “accelerated approval” of the […]